Background: Cardiovascular disease (CVD) is the leading cause of death worldwide,responsible for over 17 million deaths per year. At the beginning of the 20th century,cardiovascular disease was responsible for less than 10% of all deaths worldwide, but bythe start of the 21st century, CVD was responsible for about 30% of all deathsworldwide. Anti-platelet drugs are often used to prevent and/or treat cardiovasculardiseases, and these drugs are in high demand. Although oral and IV anti-plateletmedications may prevent the formation of blood clots, blood platelets of patients withmechanical circulatory support devices are subject to higher levels of shear physical stress.This leads to a higher incidence of platelet activation and aggregation, which may lead toincreased thrombosis.
Invention: This novel invention provides a method to limit the effects of shear stress fromMCS devices on the platelet cells of patients with congestive heart failure. The invention hasbeen shown to reduce platelet activation and aggregation in vivo by mitigating the effects ofshear stress by increasing platelet membrane fluidity
Application: Shear stress on platelets is common in patients with congestive heart failurewho have been implanted with a MCS device. Although MCS devices can prolong life forpatients who are awaiting a heart transplant, the pressure associated with these devices cancause platelet membrane fragmentation or disruption into the bloodstream, which maycause both local and distant blood clot formation. This can lead to both reduced MCS deviceflow functionality, as well as potential death of the patient due to reduced cardiac output,stroke, and/or heart attack. This invention can be applied to reduce or prevent thrombosisin this patient population.
Advantages: This invention offers a significant benefit to patients who need mechanicalcirculatory support devices. By preventing platelet activation and aggregation, thistechnology could allow clinicians to more confidently use MCS devices, including using thedevices for a longer duration and/or at higher rates of pump functionality to maximizecardiac benefit and reduce the risk of thrombosis.